Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Equipe labellisée Ligue contre le Cancer, France.
Adv Mater. 2024 Oct;36(40):e2406604. doi: 10.1002/adma.202406604. Epub 2024 Aug 20.
In recent decades, subcutaneous (SC) administration of monoclonal antibodies (mAbs) has emerged as a promising alternative to intravenous delivery in oncology, offering comparable therapeutic efficacy while addressing patient preferences. This perspective article provides an in-depth analysis of the technological landscape surrounding SC mAb administration in oncology. It outlines various technologies under evaluation across developmental stages, spanning from preclinical investigations to the integration of established methodologies in clinical practice. Additionally, this perspective article explores emerging trends and prospective trajectories, shedding light on the evolving landscape of SC mAb administration. Furthermore, it emphasizes key checkpoints related to quality attributes essential for optimizing mAb delivery via the SC route. This review serves as a valuable resource for researchers, clinicians, and healthcare policymakers, offering insights into the advancement of SC mAb administration in oncology and its implications for patient care.
近几十年来，皮下（SC）给药已成为肿瘤学中替代静脉给药的一种有前途的方法，在提供相当疗效的同时还满足了患者的偏好。本文深入分析了肿瘤学中 SC 单克隆抗体给药的技术现状。它概述了不同技术的评估进展，涵盖了从临床前研究到将成熟方法应用于临床实践的各个阶段。此外，本文还探讨了新兴趋势和未来方向，阐明了 SC 单克隆抗体给药领域的演变情况。此外，本文还强调了与通过 SC 途径优化单克隆抗体输送的关键质量属性相关的重要检查点。这篇综述为研究人员、临床医生和医疗保健政策制定者提供了宝贵的资源，深入了解了肿瘤学中 SC 单克隆抗体给药的进展及其对患者护理的影响。
